Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 12/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ESRRG | P62508 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391599 | 1.00 | ADRB2 (0.46) | ADRB2ADRB1NPC1RAB9APARP1 | |
| SCHEMBL4385662 | 0.93 | ADRB2 (0.45) | ADRB2ADRB1NPC1RAB9APARP1 | |
| SCHEMBL4385667 | 0.93 | ADRB2 (0.45) | ADRB2ADRB1NPC1RAB9APARP1 | |
| SCHEMBL4394564 | 0.93 | ADRB2 (0.52) | ADRB2ADRB1PARP1CHRM3ESRRG | |
| SCHEMBL4394561 | 0.93 | ADRB2 (0.52) | ADRB2ADRB1PARP1CHRM3ESRRG | |
| SCHEMBL4390573 | 0.93 | ADRB2 (0.45) | ADRB2ADRB1NPC1RAB9APARP1 | |
| SCHEMBL4390578 | 0.93 | ADRB2 (0.45) | ADRB2ADRB1NPC1RAB9APARP1 | |
| SCHEMBL4389689 | 0.91 | ADRB2 (0.44) | ADRB2ADRB1PARP1CHRM3TRPV1 | |
| SCHEMBL4389683 | 0.91 | ADRB2 (0.44) | ADRB2ADRB1PARP1CHRM3TRPV1 | |
| SCHEMBL4387414 | 0.91 | ADRB2 (0.46) | ADRB2ADRB1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | ADRB2 731/4885ADRB1 711/4885NPC1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.